SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

AZTR

Azitra, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for initial first-in-human results for ATR-COSF by year-end 2026 and any further updates on ATR-04 trial enrollment or data. The expanded trial population for ATR-04 could broaden its addressable market if successful, but the company remains pre-revenue and dependent on funding.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

AZTR drug pipeline →

ATR-04

◆ Mixed Named in this press release
Impact
Phase
Phase 1/2
Time to market
Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
Next catalyst
None dated

What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6000
T+0 close · Nov 10, 2026 · via day close
Latest settled
−2.47%
T+1 · $0.5852
Vs SPY
−3.79%
α at T+1
Next horizon
T+5
due 9h ago
  1. T+0 · Nov 10 $0.6000entry
  2. T+1 · 6d ago −2.47%α −3.79% · $0.5852
  3. T+5 · due 9h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azitra issued a press release announcing a presentation at BIO-Europe 2026 highlighting initial ex vivo data for ATR-COSF, a recombinant filaggrin protein for cosmetic use, showing a 56% reduction in wrinkles from baseline. The company also provided an update on its Phase 1/2 trial of ATR-04, which was expanded to include patients with rashes from KRAS and MEK inhibitors. No financial results or guidance were provided.

Key Facts

  • ATR-COSF showed a 56% reduction in wrinkles from baseline in an ex vivo human torso skin model.
  • ATR-COSF improved elasticity and wrinkle depth compared to vehicle in ex vivo models at 48 hours.
  • Phase 1/2 trial of ATR-04 expanded in October 2026 to include patients with rashes due to KRAS and MEK inhibitors, and NF1 patients with rash from MEK inhibitors.
  • Approximately 85,000 patients undergo KRAS or MEK inhibitor treatment annually in the U.S., in addition to ~220,000 on EGFR inhibitors.
  • Initial results from the first-in-human study of ATR-COSF are anticipated by year-end 2026.
  • No financial results, revenue, EPS, or guidance were reported in this press release.

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage biopharma with $4M market cap.

Risk Factors

  • Pre-revenue clinical-stage company with $4M market cap; requires additional funding to continue operations.
  • Ex vivo results may not translate to human clinical outcomes; first-in-human study results pending.
  • ATR-04 trial expansion adds complexity and may not accelerate enrollment or yield favorable data.
  • Forward-looking statements subject to risks including trial delays, regulatory hurdles, and competition.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302934728

Track record

16 reports on AZTR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
  3. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  4. Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
  5. Nov 10, 20267d ago 8-K Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  6. Nov 10, 20267d ago Press Release Neutral 3/10 Viewing Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  7. Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
  8. Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
  9. Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
  10. Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026